Wegovy vs. Zepbound: Which One Actually Wins in 2026?

Wegovy vs. Zepbound: which costs less?

Over a year, Wegovy costs less when you pay cash. When insurance covers the drug and you use the maker's savings card, the two meet at $25 a month. On Medicare, both cost $50 through the GLP-1 Bridge. Here is each way to buy them.

• Wegovy pill, NovoCare self-pay. A daily semaglutide tablet. The first month costs about $150. The second costs about $200. From the third month, it's about $300. It's the cheapest brand-name option here if a pill suits you.
• Wegovy pen, NovoCare self-pay. The weekly shot. New patients pay about $200 for each of the first 2 fills at the starting doses, through December 31, 2026. After that it's about $350 a month. The 7.2 mg high dose costs about $400. You can get it by mail or pick it up at a local pharmacy.
• Zepbound, Lilly self-pay. It costs about $300 at 2.5 mg and about $400 at 5 mg. From 7.5 mg up, it's about $450 if you refill within 45 days of your last delivery. A late refill costs about $500 at 7.5 mg, and about $700 at higher doses. The KwikPen is also sold at Lilly's price in many local pharmacies.
• Wegovy Savings Card, if your plan covers Wegovy. It applies to commercial insurance, meaning a plan from your job or one you buy yourself. A fill can drop to $25, with Novo paying up to $100 of each monthly fill. If your plan doesn't cover Wegovy, the same offer still gets you Novo's self-pay price at a local pharmacy.
• Zepbound Savings Card, if your plan covers Zepbound. It can bring the single-dose pen to $25 a fill. Lilly pays up to $1,300 a year, and the card ends December 31, 2026. If your commercial plan doesn't cover the pen, the card brings it to about $500. See Zepbound savings for the full card rules.
• Medicare GLP-1 Bridge. Part D is Medicare's drug coverage. From July 1, 2026 to December 31, 2027, Part D members who qualify pay $50 a month. It covers the Wegovy pen and pill, the Zepbound KwikPen, and Lilly's pill Foundayo.
• Retail with no program. The list price is the price before any discount. Wegovy's is about $1,350 a month, set to drop to $675 on January 1, 2027. A GoodRx coupon gets you Novo's self-pay price instead, but not the two cheaper first pen fills. Zepbound with GoodRx runs about $995 to $1,050 a month. That's barely below its list price of about $1,085.

What a year costs on each drug

Pens come in 28-day boxes, so a year means 13 fills. These totals follow each label's dose steps.

• Wegovy pen, self-pay: about $4,250 in the first year. That counts the two intro fills, then eleven at about $350.
• Wegovy pill, self-pay: about $3,350 for twelve monthly bottles. That assumes you reach the 9 mg dose in month three.
• Zepbound, self-pay: about $5,650 in the first year. That assumes you reach 7.5 mg in month three and always refill on time. It's about $1,400 more than the Wegovy pen.
• Either drug, insured, with the savings card: as little as about $325 a year. The gap disappears.
• Either drug on the Medicare Bridge: about $650 a year. Each monthly supply costs $50.

For every price path on each drug, see Wegovy cost and Zepbound cost.

Which is better for weight loss: Wegovy or Zepbound?

SURMOUNT-5 was the first trial to test the two drugs head to head. It was published in the New England Journal of Medicine in 2025. It randomly assigned 751 adults with obesity, without diabetes, to one drug or the other for 72 weeks. Everyone knew which drug they got, a design called open-label.

People on tirzepatide, Zepbound's active ingredient, lost about 20% of their starting weight on average. People on semaglutide, Wegovy's ingredient, lost about 14%. Waists shrank more on tirzepatide too. More people on it also reached the higher weight-loss targets.

One update matters today. The trial used semaglutide at up to 2.4 mg, the top Wegovy dose at the time. In March 2026, the FDA approved a 7.2 mg Wegovy dose. In the STEP UP trial, people on 7.2 mg lost about 19% of their weight, against about 4% on placebo. It's a step up for people who already tolerate 2.4 mg, not a starting dose.

Those two results come from separate trials with different people. Even at the same 2.4 mg dose, people lost about 16% in STEP UP, against about 14% in SURMOUNT-5. So the fair reading is that the new dose narrows Zepbound's lead, not that it erases it. All of these are averages, not a promise for any one person. For the deeper drug-level comparison, see semaglutide vs. tirzepatide.

What's the actual difference between Wegovy and Zepbound?

Wegovy is Novo Nordisk's brand of semaglutide. It acts on one gut hormone signal, GLP-1, which slows digestion and quiets appetite. Zepbound is Eli Lilly's brand of tirzepatide. It does the same GLP-1 work and adds a second signal, GIP. That second signal is the leading explanation for the trial gap, though how much it adds is still being studied.

Their approved uses have also split. In March 2024, Wegovy was approved to lower the risk of heart attack, stroke and heart-related death in adults with heart disease and excess weight. That rests on the SELECT trial. In December 2024, Zepbound was approved for moderate to severe sleep apnea in adults with obesity.

Wegovy also comes as a daily pill, approved in December 2025 in 1.5, 4, 9 and 25 mg strengths. Zepbound is a shot only. It comes as a single-dose pen, a KwikPen or a vial. Lilly does sell its own weight-loss pill, Foundayo, but it's a different drug called orforglipron. If you want to avoid needles, that's a real point for Wegovy.

Does insurance cover Wegovy or Zepbound more easily?

Neither has a built-in edge. It comes down to your plan, and the answer can change each year. Prior authorization is the norm for both. That's a form your insurer must approve first, usually showing your BMI, a related health condition and sometimes past diet attempts. Larger employers are more likely to cover either drug than small ones.

Drug lists also swing. A plan's drug list, called a formulary, says which drugs it covers. CVS Caremark dropped Zepbound from its standard list in July 2025 in favor of Wegovy. It listed Zepbound as preferred again from October 1, 2026. Check your own plan's list before assuming either brand is easier. Zepbound insurance and Wegovy insurance explain how to check and appeal.

Wegovy vs. Zepbound side effects: does one hit harder?

Both drugs cause the same kind of gut side effects: nausea, vomiting, diarrhea and constipation. Slowing digestion is how they work, so this comes with the territory. In SURMOUNT-5, the most common side effects on both drugs were gut-related. Most were mild to moderate and came while the dose was going up.

Zepbound's label lists hair loss among its common side effects. In its trials, women reported it more often than men: about 7% of women on Zepbound, against about 1% on placebo. The label links it to the weight loss itself. The two drugs' labels come from different trials, so they can't rank the drugs on this. How each person tolerates each drug still varies a lot.

Can you switch from Wegovy to Zepbound, or the reverse?

Yes. Clinicians make this switch often, usually after a plateau, hard side effects or an insurance change. There's no FDA-set dose conversion between the two drugs. Most prescribers restart the new drug at its lowest dose, even if you were on the top dose of the old one. Timing and checkups vary by prescriber.

What do real people say about Wegovy vs. Zepbound on Reddit and in reviews?

Forums and review sites are full of personal stories about both drugs. They can tell you what a dose increase felt like for one person. They can't tell you which drug works better, because posters choose themselves and aren't checked.

Use them for practical tips, like injection technique or managing nausea. For the question of which drug does more, weigh the trial results above instead.

Wegovy or Zepbound: which is right for you at 40+?

Perimenopause adds its own twist. Falling estrogen is linked to more insulin resistance, when the body responds less to insulin. It's also linked to more fat stored around the middle. Both drugs act on appetite and blood sugar, which fits that picture. But SURMOUNT-5 didn't report results for women in perimenopause or after menopause separately. So there's no menopause-specific winner, only the general evidence above.

• Budget decides it. Choose Wegovy. It costs less over a year paying cash, and the pill is the lowest-cost brand-name option here.
• You want the biggest average result. Choose Zepbound. SURMOUNT-5 is the best evidence for it, though Wegovy's 7.2 mg dose has narrowed the gap.
• Your insurance already covers one. Let coverage decide. Fighting a denial for the other drug rarely beats using the one your plan pays for.
• You're on Medicare. Both cost $50 a month through the GLP-1 Bridge if you qualify. So choose on results and form, pen or pill.
• Needles are a hard no. Wegovy's pill is the only pill between the two.